Every material Form 8-K ZEVRA THERAPEUTICS, INC. has filed with the SEC since May 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Zevra Therapeutics reported third-quarter 2026 revenue, net of $37.8 million, up from $26.1 million a year earlier, and net income of $19.2 million, or $0.26 per diluted share, compared with a net loss of $0.5 million in Q3 2025. Operating expenses rose to $24.1 million from $20.4 million, and the company reported $270.9 million in cash, cash equivalents and investments as of September 30, 2026.
Q3 2026 net revenue of $37.8 million, including $34.0 million from MIPLYFFA, up from $26.1 million in Q3 2025
Net income of $19.2 million, or $0.26 per diluted share, versus a net loss of $0.5 million, or $(0.01) per share, in Q3 2025; the quarter included a $5.1 million noncash gain from warrant and CVR liability fair value adjustments
Operating expenses of $24.1 million, up from $20.4 million, with SG&A at $19.1 million and R&D at $4.9 million
Cash, cash equivalents and investments of $270.9 million as of September 30, 2026; the company hosts a conference call today at 4:30 p.m. ET
Zevra Therapeutics reported second-quarter 2026 revenue of $39.7 million, up 53% from $25.9 million a year earlier, with $30.2 million from MIPLYFFA. Net income fell to $8.8 million, or $0.14 per diluted share, from $74.7 million, or $1.21 per diluted share, in Q2 2025, which included a $148.3 million gain on the sale of a priority review voucher. Cash, cash equivalents and investments were $260.2 million as of June 30, 2026.
Total net revenue of $39.7 million for Q2 2026, up $13.8 million from $25.9 million in Q2 2025
MIPLYFFA net revenue of $30.2 million in Q2 2026; OLPRUVA net revenue of $0.2 million
Net income of $8.8 million ($0.14 per diluted share) vs. $74.7 million ($1.21) in Q2 2025, which included a $148.3 million priority review voucher sale gain
Cash, cash equivalents and investments of $260.2 million as of June 30, 2026
Zevra Therapeutics reported first-quarter 2026 net revenue of $36.2 million, up from $20.4 million a year earlier, and net income of $37.9 million, compared with a net loss of $3.1 million in Q1 2025. The profit includes a one-time $43.3 million gain on the $50.0 million sale of its SDX portfolio to Commave Therapeutics, and the company prepaid its $63.1 million term loan in full.
Net revenue of $36.2 million for Q1 2026, versus $20.4 million in Q1 2025.
Net income of $37.9 million, or $0.60 per diluted share, versus a net loss of $3.1 million in Q1 2025.
Excluding one-time items, the company estimated adjusted net income of $11.5 million, or $0.18 per diluted share (non-GAAP).
Cash, cash equivalents and securities were $236.8 million as of March 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ZEVRA THERAPEUTICS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →